Vicarious Surgical Inc. (RBOT)
NYSE: RBOT · IEX Real-Time Price · USD
0.269
-0.010 (-3.48%)
Apr 19, 2024, 2:33 PM EDT - Market open
Vicarious Surgical Stock Forecast
RBOT's stock price has decreased by -87.99% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Vicarious Surgical stock have an average target of 2.75, with a low estimate of 0.40 and a high estimate of 9.00. The average target predicts an increase of 921.17% from the current stock price of 0.27.
Analyst Consensus: Hold
* Price targets were last updated on Mar 5, 2024.
Analyst Ratings
The average analyst rating for RBOT stock from 5 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 3 | 3 | 3 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Maintains $1.5 → $1 | Hold | Maintains | $1.5 → $1 | +271.33% | Mar 5, 2024 |
| Morgan Stanley | Morgan Stanley | Hold Initiates $0.6 | Hold | Initiates | $0.6 | +122.80% | Dec 4, 2023 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 14, 2023 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $9 → $0.4 | Strong Buy → Hold | Downgrades | $9 → $0.4 | +48.53% | Nov 14, 2023 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $9 | Strong Buy | Maintains | $12 → $9 | +3,242.00% | May 31, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.39
from -0.49
EPS Next Year
-0.41
from -0.39
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | 37.8M | 58.0M |
| Avg | n/a | n/a | n/a | 31.2M | 56.3M |
| Low | n/a | n/a | n/a | 20.5M | 54.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 85.5% |
| Avg | - | - | - | - | 80.2% |
| Low | - | - | - | - | 73.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.36 | -0.38 | -0.33 | -0.32 |
| Avg | -0.39 | -0.41 | -0.42 | -0.34 |
| Low | -0.47 | -0.48 | -0.51 | -0.36 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | - |
| Avg | - | - | - | - |
| Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.